And so we know about some patients already anecdotally who have passed away on the waiting list, which is very sad, but now this is a tough time as the world has turned their attention to COVID. And our real world outcomes and these patients have been outstanding with the balloon-expandable SAPIEN 3. We're starting to see positive signs already. Information concerning factors that could cause these differences and important product safety information may be found in the press release, our 2019 annual report on Form 10-K and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more! The way it was paused, we're going to be able to open up individual centers when they're ready. The recovery of our structural heart businesses will be influenced by many factors and tempered by the time it takes for patients to seek and receive treatment. As we move beyond COVID-19 and even as transcatheter technology expands, we are excited about our ability to provide innovative surgical treatment options for more patients and extend our global leadership in premium Surgical Structural Heart technologies. You emphasized a couple of times that there will be informative updates, which sounds like, I don't know, strong language to me at EuroPCR on PASCAL, Cardioband and EVOQUE. Okay. And so you're going to get a snapshot each year into the future. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today. 1 How Many Times Edwards Lifesciences Corporation (EW) Stock's Were Split? But the other thing that we have to be clear on is we've watched the system really screeched to a halt. And Scott, I love hearing when companies do right by their employees during tough times. So the -- you know if it varies different -- it differ, as you can imagine by geography. You know us, we're so focused on structural heart diseases, that's where we really put our energy. Okay, thanks. Michael A. Mussallem -- Chairman and Chief Executive Officer. As you might expect, procedure volumes in March vary greatly by geography even by hospital as patients and providers turn their focus to the pandemic. Sure. However, in my checks, I'm hearing that the most urgent patients, i.e. But maybe just help us put it all together down the P&L and how you reach the EPS? In critical care, first quarter sales of $183 million increased 1% on an underlying basis. Sure. We are grateful to our employees who are making progress to more than double our production to keep up with this demand and serve critically ill patients in need. And so what I will share here will be somewhat anecdotal. I also want to recognize the extraordinary actions of our 14,000 employees around the world that have taken to overcome the unique challenges associated with COVID-19. We're proactively managing our capacity and our supply chain. Yeah. Thanks, Victor. About Edwards Lifesciences Yeah. We continue to gain experience and make meaningful progress across the portfolio, and you can expect to hear informative updates regarding PASCAL, Cardioband and EVOQUE at the upcoming EuroPCR medical meeting. Certainly, there are very sick patients that aren't being done, right, we're not doing zero. Despite challenges associated with COVID-19, we reported $1.1 billion in sales this quarter, representing 14% sales growth. I was hoping you could give us a little bit of what has to happen from this point to get to $700 million, what has to happen to get to $900 million? In Transcatheter Aortic Valve Replacement or TAVR, our first quarter global sales were $742 million, up 25% on an underlying basis. I guess I wanted to build on this comments you made about the fourth quarter and getting back to where you thought you would have been kind of prior to this. Stock Advisor launched in February of 2002. I guess I'm a little more bullish on the recovery curve as you probably saw with my upgrade. This rate included 270 basis point benefit from the accounting for employee stock-based compensation, which was 130 basis points or $0.04 unfavorable to our guidance expectation. Just if I could, I just have one question. Average shares outstanding in Q1 was 211.7. I also want to commend our clinical field teams for their work, providing real-time support for patients and frontline clinicians at this time when its needed most. Could Edwards Lifesciences Be a Millionaire-Maker Stock? One on new centers. So just trying to get a sense of how confident you are that that is going to be the case, because it sounds to me like a lot of those very sick patients are actually getting done? We currently estimate that there is more than 700 centers and we said that -- and this was following the NCD that was approved last year that we're probably headed toward 850 in total. Edwards Lifesciences Corp. stockholders approved a plan to execute a 3-for-1 split of the company's common stock. Thanks for fitting me in here. Our U.S. TAVR sales growth through early March was consistent with our strong fourth quarter growth rate, driven by a step up in TAVR treatments as new patients entered the system independent of their surgical risk. We appreciate their strong leadership and brave commitment to patient care and we are dedicated to supporting them as they address this global health crisis. My apologies. And then, I just want to go back to your comments on procedures. We anticipate that our Q4 sales will return to positive growth driven by market adoption of our newest technologies. Do you have any sense for in your framework that you laid out here when you might be able to get those restarted? Thanks, Rick. Good evening. We think that there is going to be a more pronounced effect in Q2. While the pandemic remains active, revenues from our enhanced surgical recovery products will be significantly lower, partially offset by increased demand for ICU products. Finally, I want to recognize the important role and impact of our charitable partners in meeting both local and global community needs at this time. I know if you just run the numbers here, it gets to be an extraordinary large group of patients and that distresses us greatly. During today's call, management will discuss the results included in the press release and accompanying financial statements and then use the remaining time for Q&A. Edwards Lifesciences (EW) – The medical technology company begins post-split trading today, following a 3-for-1 stock split declared earlier this month that saw new shares distributed Friday. Any change in terms of all in terms of the competitive headwinds, because we just imagine that getting cases proctored and moving forward with the launch could be a little bit challenging for the competitors. I wanted to follow-up on Bob's question about second quarter. A split is applied today to Edwards Lifesciences Corporation's stock price. I can summarize it this way. But the section you are going to see has a more straightforward approach. We have also seen some delay in HemoSphere orders in the U.S. as hospitals limit their capital spending as they focus on COVID-19. Yeah, the numbers did come closer together. We have modeled multiple scenarios based on the pace at which hospitals return to more normal treatment rates. Thanks for taking the question. Recall that HARPOON offers the potential for earlier treatment of degenerative mitral valve disease with faster recovery and more consistent outcomes for surgical patients. It's difficult to quantify the impact on patients at this time, but recall data published in The Annals of Thoracic Surgery suggests that patients waiting for aortic valve replacement have a 4% mortality risk at one month, 8% at three months and 12% after waiting six months. Okay. Cumulative Growth of a $10,000 Investment in Stock Advisor, Edwards Lifesciences Corp (EW) Q1 2020 Earnings Call Transcript @themotleyfool #stocks $EW, Edwards Lifesciences Blows Past Q2 Earnings Estimates, Edwards Lifesciences Corp (EW) Q2 2020 Earnings Call Transcript, Abbott Laboratories and Edwards Lifesciences Settle Patent Fight. Thank you. In terms of SG&A, we've had some natural declines just in travel and conferences and the timing on headcount growth because we're still a growth company.